Indian Drug Makers
- All
- News
- Videos
-
New Drug-Making Standards For Indian Pharma Firms After Overseas Deaths
Indian pharmaceutical companies must meet new manufacturing standards this year, according to a government notification released on Saturday, although small companies have asked for a delay, citing their debt load.
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
-
US Delays Use Of India-Made COVID-19 Vaccine Covaxin. What It Recommended
In a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data.
-
US Regulator's Scrutiny On Indian Drug Makers To Remain Intense: Crisil
Regulatory scrutiny of the US Food and Drug Administration (FDA) for domestic pharmaceutical facilities is expected to remain intense over the medium term, rating agency Crisil said on Wednesday.
-
Sensex Heads For Second Straight Fall; Lupin Drags
Indian shares fell on Wednesday and were headed for their second straight session of declines, as drug maker Lupin Ltd dropped on concerns about its earnings outlook and as investors weighed whether the recent rally in equities may have been overdone.
-
Sensex Ends Over 100 Points Higher On Buying In Pharma Shares
Indian shares rose on Wednesday on the back of broad-based buying while pharma stocks outperformed as drug makers such as Glenmark Pharmaceuticals and Aurobindo Pharma gained after getting approvals for generic versions of a blockbuster cholesterol drug in the U.S.
-
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
-
Advent, Baxter Set To Submit Bids For India's Gland Pharma: Report
Global buyout firm Advent International and U.S.-based Baxter International are among suitors preparing to submit separate bids to buy unlisted Indian drugmaker Gland Pharma Ltd, three people with direct knowledge of the matter told Reuters.
-
Two Indian Generics Makers End Battle to Copy Drugs Amid Patent Debate
Two Indian drug makers said they had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma.
-
South Africa's Adcock Ingram Sells Indian Unit for $22 Million
South African drug maker Adcock Ingram on Wednesday said it sold its Indian unit for 336 million rand ($22 million or around Rs 146 crore) to a private equity firm, after the Bangalore-based business suffered two write downs since 2013.
-
India Agreed to Not Issue 'Compulsory' Drug Licences: US Industry Body
The Indian government has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drug makers, a US business advocacy group said.
-
More Inspections Due to Rising Drug Imports From India: USFDA
The USFDA had taken action against companies like Sun Pharma and Ranbaxy.
-
Government Says Custom Duty Relief Removed to Protect Indian Drugmakers
Under flak for withdrawing customs duty exemption for 76 life saving drugs including for cancer, the government on Wednesday justified the decision, saying it was to protect domestic manufacturers and there will only be marginal increase in the prices of these imported drugs.
-
US Regulator Warns IPCA Labs on Manufacturing Lapses at 3 Plants
Drug maker IPCA Laboratories Ltd said the US Food and Drug Administration (FDA) issued it a warning letter outlining manufacturing quality lapses observed at three of its Indian factories, pushing its shares down as much as 16 per cent.
-
India's 100 Richest Includes Only 4 Women
Four women feature in this year's Forbes list of 100 richest Indians including O P Jindal group Chairperson Savitri Jindal and generic drugs maker USV Pharma Chairperson Leena Tewari.
-
New Drug-Making Standards For Indian Pharma Firms After Overseas Deaths
Indian pharmaceutical companies must meet new manufacturing standards this year, according to a government notification released on Saturday, although small companies have asked for a delay, citing their debt load.
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
-
US Delays Use Of India-Made COVID-19 Vaccine Covaxin. What It Recommended
In a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data.
-
US Regulator's Scrutiny On Indian Drug Makers To Remain Intense: Crisil
Regulatory scrutiny of the US Food and Drug Administration (FDA) for domestic pharmaceutical facilities is expected to remain intense over the medium term, rating agency Crisil said on Wednesday.
-
Sensex Heads For Second Straight Fall; Lupin Drags
Indian shares fell on Wednesday and were headed for their second straight session of declines, as drug maker Lupin Ltd dropped on concerns about its earnings outlook and as investors weighed whether the recent rally in equities may have been overdone.
-
Sensex Ends Over 100 Points Higher On Buying In Pharma Shares
Indian shares rose on Wednesday on the back of broad-based buying while pharma stocks outperformed as drug makers such as Glenmark Pharmaceuticals and Aurobindo Pharma gained after getting approvals for generic versions of a blockbuster cholesterol drug in the U.S.
-
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
-
Advent, Baxter Set To Submit Bids For India's Gland Pharma: Report
Global buyout firm Advent International and U.S.-based Baxter International are among suitors preparing to submit separate bids to buy unlisted Indian drugmaker Gland Pharma Ltd, three people with direct knowledge of the matter told Reuters.
-
Two Indian Generics Makers End Battle to Copy Drugs Amid Patent Debate
Two Indian drug makers said they had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma.
-
South Africa's Adcock Ingram Sells Indian Unit for $22 Million
South African drug maker Adcock Ingram on Wednesday said it sold its Indian unit for 336 million rand ($22 million or around Rs 146 crore) to a private equity firm, after the Bangalore-based business suffered two write downs since 2013.
-
India Agreed to Not Issue 'Compulsory' Drug Licences: US Industry Body
The Indian government has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drug makers, a US business advocacy group said.
-
More Inspections Due to Rising Drug Imports From India: USFDA
The USFDA had taken action against companies like Sun Pharma and Ranbaxy.
-
Government Says Custom Duty Relief Removed to Protect Indian Drugmakers
Under flak for withdrawing customs duty exemption for 76 life saving drugs including for cancer, the government on Wednesday justified the decision, saying it was to protect domestic manufacturers and there will only be marginal increase in the prices of these imported drugs.
-
US Regulator Warns IPCA Labs on Manufacturing Lapses at 3 Plants
Drug maker IPCA Laboratories Ltd said the US Food and Drug Administration (FDA) issued it a warning letter outlining manufacturing quality lapses observed at three of its Indian factories, pushing its shares down as much as 16 per cent.
-
India's 100 Richest Includes Only 4 Women
Four women feature in this year's Forbes list of 100 richest Indians including O P Jindal group Chairperson Savitri Jindal and generic drugs maker USV Pharma Chairperson Leena Tewari.
